Grifols Reports Strong Q3 Results with Biopharma Growth
Company Announcements

Grifols Reports Strong Q3 Results with Biopharma Growth

Grifols (ES:GRF) has released an update.

Grifols, a global leader in plasma-derived medicines, reported a strong third quarter in 2024, with a 12.1% growth in Biopharma driving total revenues to 1.793 billion euros. The company achieved a 26.7% increase in adjusted EBITDA due to a better product mix and reduced plasma costs, while net profit reached 88 million euros despite non-recurring expenses. Grifols remains focused on deleveraging and generating free cash flow, reaffirming its robust financial outlook for the year.

For further insights into ES:GRF stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyGrifols price target raised to EUR 10 from EUR 9 at Deutsche Bank
TheFlyGrifols holder Mason Capital opposes potential transaction, tells board
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App